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A Ab bs st tr ra ac ct t    Periconceptional use of folic acid alone or in multivitamin supplements is 
effective for the primary prevention of neural-tube defects. The 
Hungarian randomized and two-cohort controlled trials showed that 
periconceptional multivitamin supplementation can reduce the 
occurrence of some other structural birth defects, i.e. congenital 
abnormalities. These findings were supported by many, but not all 
observational studies. Recently there have been two main debated 
questions. The first one is whether the use of folic acid alone or folic acid-
containing multivitamins is better. The second one is connected with the 
dilemma of whether high dose of folic acid (e.g. 5 mg) might be better 
than a daily multivitamin with 0.4 – 0.8 mg of folic acid. Comparison of 
the pooled data of two Hungarian trials using a multivitamin containing 
0.8 mg folic acid and the data of the Hungarian Case-Control Surveillance 
of Congenital Abnormalities using high dose of folic acid seemed to be 
appropriate to answer these questions. Multivitamins containing 0.4 – 
0.8 mg of folic acid were more effective for the reduction of neural-tube 
defects than high dose of folic acid. Both multivitamins and folic acid can 
prevent some part of congenital cardiovascular malformations. Only 
multivitamins were able to reduce the prevalence at birth of obstructive 
defects of urinary tract, limb deficiencies and congenital pyloric stenosis. 
However, folic acid was effective in preventing some part of rectal/anal 
stenosis/atresia, and high dose of folic acid had effect in preventing some 
orofacial clefts. The findings are consistent that periconceptional 
multivitamin and folic acid supplementation reduce the overall 
occurrence of congenital abnormalities in addition to the demonstrated 
effect on neural-tube defects. 
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1.  Introduction 
Each year among 135 million new births in the world, about 3% are affected with major structural 
birth defects, called congenital abnormalities (CAs). We can estimate more than 4 million each year or 
11,376 daily of children born with CA. At present the total group of CAs is the major cause of infant 
mortality and disabilities among children in the industrialized countries. Therefore the prevention of 
CAs is an extremely important public health issue, since obviously we can secure the health in healthy 
born people. 
There was a tremendous progress in the antenatal diagnosis of fetal defects due to ultrasound 
scanning, chromosomal and gene analyses, etc. However, parents – once informed that the fetus is 
severely affected by a defect – have to choose between two “evils”, i.e. to have a malformed baby who 
will require long term medical care and have to deal with the social consequences of the defects, or to 
terminate the pregnancy. The great majority of prospective parents elect for termination of the 
pregnancy. Of course, this is a last resort rather than an optimal accomplishment. We have to do 
therefore our best to introduce the only one good solution, the primary prevention of CAs. No doubt 
that the primary prevention is better than the termination of pregnancy after the antenatal diagnosis of 
fetal defects (i.e. the so-called “secondary prevention”, namely the prevention of birth of malformed 
fetuses). In addition, the cost and medical complications are much lower and there is no moral or guilty 
consequence due to the devastation of a human being. 
In the early 1990s two randomized clinical trials have indicated the effectiveness of high dose of 
folic acid [1] or folic acid-containing multivitamin supplementation [2] during the periconceptional 
period in the primary prevention of recurrent [1] and first occurrence [2] of neural-tube defects (NTDs). 
The Hungarian randomized clinical trial has also demonstrated that the risk for CAs of cardiovascular 
system and urinary tract was reduced significantly, in addition limb reduction CAs and congenital 
pyloric stenosis showed a decreasing trend after the periconceptional multivitamin supplementation [3-
5]. These findings have been confirmed by several observational studies [6] and by the second 
Hungarian intervention, the so-called two-cohort controlled trial [7]. The data of the large population-
based Atlanta Birth Defects Case-Control Study also showed a reduction in some CA groups beyond 
NTDs [8]. However, we were not able to confirm the previous finding of Tolarova [9] regarding the 
preventive effect of very high dose (10 mg) of folic acid and other vitamins for recurrent cleft lip ± 
palate in our intervention trials using a low dose of folic acid (0.8 mg) containing multivitamin. In other 
studies on orofacial clefts, the preventive effectiveness of multivitamin supplementation varied 
considerable from 1.3 (i.e. 30% increased risk) [10] to 0.7 (i.e. 30 % decreased risk).[11]
 
The primary prevention of CAs other than NTDs is extremely important because for example 
cardiovascular CAs account a larger fragment of infant mortality than any other CAs including NTDs. 
In addition, there was a reduction in risk for imperforate anus after the periconceptional folic acid (0.4 
mg) supplementation in China [12]. Some reduction was found in the occurrence of nonsyndromic 
omphalocele in a US population-based case-control study [13]. These CAs are considered as candidate 
CAs for the primary prevention by folic acid containing multivitamins or folic acid alone. An excellent 
review paper about multivitamin supplementation and risk for CAs other than NTDs was published in 
2004 [6].  
Recently there have been two main debated questions regarding the primary prevention of CAs. 
The first question is whether the use of folic acid alone or folic acid-containing multivitamins is better 
[14]. The second question is connected with the dilemma of whether the high dose of folic acid (5 mg) 
[15-16] might be better than a daily multivitamin with 0.4-0.8 mg of folic acid. As far as I know the 
Hungarian data sets are unique to answer these questions. On the one hand now the results of the two 
Hungarian intervention trials are available and their pooled data are appropriate for the estimation of 
effectiveness of a folic acid (0.8 mg) containing multivitamin supplementation during the 
periconceptional period for the primary prevention of NTD and other candidate CAs [14]. On the other 
hand the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital 
Abnormalities (HCCSCA) [17] can provide a chance for the estimation of effectiveness of high dose of 
folic acid supplementation during the periconceptional period for the prevention of CAs. 
Here I will summarize the methods and results of the two Hungarian intervention trials. In 
addition, I will describe the methods and the recent results of the HCCSCA from this aspect. 
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2.  Materials and methods 
a) Intervention trials 
The participants in the Hungarian periconceptional care program took part voluntarily in a 
randomized controlled trial (RCT) [2], and later in the two-cohort controlled trial (TCT) [7]. Participant 
women were periconceptionally supplemented with the same multivitamin (Table 1). Each 
supplemented woman was matched with a control pregnant woman who was not supplemented with 
multivitamin, folic acid or other micronutrients during the periconceptional period in the TCT, these 
women were selected from regional antenatal care clinics.  
b) The HCCSCA 
HCCSCA is based on the Hungarian Congenital Abnormality Registry (HCAR) [18] which is a 
national-based registry of cases with CAs. Notification of CAs is mandatory for physicians, and most 
are reported by obstetricians (in Hungary practically all deliveries occur in inpatient obstetric clinics) 
and pediatricians (who are working in the neonatal units of inpatient obstetric clinics and various 
inpatient and outpatient pediatric clinics). Autopsy was mandatory for all infant deaths and usual in 
stillborn fetuses during the study period. Pathologists sent a copy of the autopsy report to the HCAR if 
defects were identified in stillbirths and infant deaths. Since 1984 reported fetal defects from antenatal 
diagnostic centers have also been included to the HCAR. Thus, the recorded total prevalence of cases 
with CA was 35 per 1000 informative offspring (liveborn infants, stillborn fetuses and electively 
terminated malformed fetuses) and about 90% of major CAs were reported to the HCAR during the 17 
years of the study period between 1980 and 1996. Cases with isolated minor anomalies (or variants) 
such as umbilical hernia, hydrocele, simian crease, etc. were excluded from the data set of the HCAR. 
The HCCSCA procedure included five steps: 
The first step was the identification of cases from the data set of the HCAR that were reported in 
the first 3 months after births or termination of pregnancies. These cases comprised 77% of the HCAR 
[17]. Cases of isolated CAs and multiple CAs were included in the data set of the HCCSCA. However, 
three mild CAs (such as congenital dislocation of the hip based on the Ortolani click, congenital 
inguinal hernia, and hemangiomas), and CA-syndromes of Mendelian and chromosomal origin were 
excluded.  
The second step was to ascertain appropriate controls from the National Birth Registry of the 
Central Statistical Office. In general, two newborn infants without CAs were matched to every case 
according to sex, birth week and district of parents' residence after 2 months of case notification. (Three 
newborn infants were selected for each case between 1986 and 1992.) 
The third step was to obtain exposure data from three sources. (i) A post-paid questionnaire with 
an explanatory letter and a list of medicines (drugs and pregnancy supplements) and diseases was 
mailed immediately after the selection of cases and controls. The questionnaire requested information 
on, among others, medicine intakes, pregnancy complications, and maternal diseases during pregnancy 
according to gestational month, and any family history of CAs. In order to standardize the answers, 
mothers were asked to read the enclosed lists of medicines and diseases as a memory aid before they 
replied. The mean ± SD time elapsed between the birth or pregnancy termination and return of the 
questionnaire was 3.5 ± 1.2 and 5.2 ± 2.9 months in the case and control groups, respectively. (ii) 
Furthermore, mothers were requested to send us the antenatal care logbook and every medical record 
concerning their diseases during pregnancy and their child's CA. Obstetricians in antenatal care are 
obliged to record all prescribed medicines for women regarding pregnancy, pregnancy-related 
complications and diseases in the logbook. Data from the antenatal care logbook were available in 
88.4% of cases and in 93.8% of controls. (iii) Regional district nurses were asked to visit and to 
question all case families and 200 control families who did not respond. Overall, information was 
available on 96.3% of cases who could be located (84.4% from reply, 11.9% from visit), and 83.1% of 
controls who could be located and from information was sought (82.6% from reply, 0.5% from visit). 
The ethics committee considered this follow-up to be disturbing for the parents of all healthy control 
children [19].
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1. The source of information. Three groups were differentiated: (i) data only from the antenatal 
care logbook and/or other medical records; (ii) data only from the questionnaire; and (iii) concordant 
data from both the medical records and the questionnaire.  
2. The type of treatment. Two groups were differentiated in the analysis: folic acid alone and folic 
acid plus other medicines.  
3. The route of administration. Only tablet for oral use was marketing.  
4. The dose. In Hungary, folic acid was available as a 3 mg tablet. 
5. The duration of treatment.  
6. The gestational age. This was calculated from the first day of last menstrual period. Three time 
intervals were considered: (i) The first month of pregnancy, as an indicator of preconceptional use of 
folic acid. The first two weeks are before conception, and the second two weeks comprise the 
preimplantation and implantation periods. (ii) The second month of gestation, including from the first 
day of the third week until the last day of the sixth week of fetal development (but from the fifth week 
until the eight week of gestational age) and it overlaps with the so-called critical period of some major 
CAs, such as NTDs and cleft lip ± cleft palate or it precedes the critical period of other CAs, e.g. 
posterior cleft palate and hypospadias. (iii) The third through ninth months of gestation.  
7. Potential confounding factors. Maternal age, birth order, marital and employment status, 
maternal disorders and other medicine (drug and pregnancy supplement) uses were evaluated. 
The fifth step was the statistical analysis of data using the SAS version 8.02 statistical software 
package (SAS Institute Ins., Cary, NC, USA). Potential confounders were evaluated using Student’s t-
test for quantitative variables and odds ratios (ORs) with 95% confidence interval (CI) for categorical 
variables between the supplemented and unsupplemented groups. The occurrence of folic acid 
supplementation in the total control group was compared with the frequency of this supplementation in 
25 CA-groups during the first and second month of gestation and adjusted odds ratios (ORs) with 95% 
confidence interval (CI) for potential confounders were evaluated in an ordinary logistic regression 
model.  
The data set of the HCCSCA between 1980 and 1996 is evaluated here because the method of data 
collection was changed after 1996. 
3.  Results 
a) Intervention trials 
The results of these two intervention trials with regard to the primary prevention of NTDs are 
shown in Table 2. The pooled findings of these trials indicate that approximately 92% of NTDs may be 
prevented using a micronutrient (“multivitamin”) combination containing a physiological dose (0.8 mg) 
of folic acid during the periconceptional period.  
Another important finding of the RCT was a significant reduction in the total (birth + fetal) 
prevalence of CAs (20.64/1,000 in the supplemented group compared with 40.57/1,000 in the 
unsupplemented group (i.e. OR: 0.53 with 95% CI: 0.35, 0.70) and this cannot be explained by the 
reduction of NTD offspring. The total reduction in CAs without NTD cases was 19.93/1,000 which 
exceeded the total prevalence of NTD (2.78/1,000) in Hungary by 7.2 fold. Isolated CAs of the urinary 
tract and cardiovascular system also showed a significant decrease while the occurrence of limb 
reduction CAs and congenital pyloric stenosis was somewhat but not significantly lower (Table 3).  
The main goal of the TCT was to differentiate the chance and vitamin dependent effect of 
periconceptional multivitamin supplementation in the prevention of the above-mentioned candidate 
CAs and to identify preventable specific CA types within these CA groups (Table 3). The findings of 
the TCT partly confirmed the previous results of the RCT because a significant reduction was found in 
the group of cardiovascular CAs particularly for ventricular septal defects. The reduction in urinary 
tract CAs did not reach the level of significance but the obstructive CAs of the pelvicureteric junction 
showed a significant decrease in agreement with the findings of the RCT. The number of offspring was 
not enough to evaluate limb reduction CAs and congenital pyloric stenosis. Our results again did not 
show prevention for isolated orofacial clefts.  
In conclusion, recent data provide encouragement for the concept that a considerable proportion of 
major CAs – beyond NTDs – are preventable by multivitamins containing low dose of folic acid. 
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The case group consisted of 22,843 malformed offspring. The prevalence of folic acid treatment 
during pregnancy was 49.4% in the case group (11,279 pregnant women). Of 38,151 controls, 20,775 
(54.5%) had mothers with folic acid supplementation.  
The proportion of medically recorded folic acid use was 27.1% and 32.1% during the first month 
of gestation in the case and control groups, while these figures were 43.3% and 66.3% during the 
second month, respectively.  
Of 22,843 cases, 1,733 (15.4%) had mothers who used only folic acid during pregnancy, while this 
figure was 4,088 (19.7%) among 38,151 controls.  
The dose of folic acid was not reported or recorded in about 50% of pregnant women. In our 
validation study based on 600 pregnant women, 22.5%, 68.6% and 8.9% used 1 (3 mg), 2 (6 mg) and 3 
(9 mg) tablets of folic acid, respectively. 
Of 22,843 cases, 684 (3.0%) had mothers with preconceptional folic acid supplementation, i.e. 
during the first month of gestation. Only 4 (0.6%) did not continue the folic acid supplementation in the 
second month, while 464 (67.8%) continued the use of folic acid until the end of pregnancy. Of 1,222 
cases who had mothers with the onset of folic acid supplementation in the second month, 394 (32.2%) 
did not continue it in the third month while 660 (54.0%) continued folic acid use until the end of 
pregnancy. Of 38,151 controls, 1,526 (4.0%) had mothers with preconceptional folic acid 
supplementation, 10 (0.7%) stopped in the second month while 1,152 (75.0%) continued folic acid 
supplementation until the end of pregnancy. Of 2,617 cases with mothers who started the use of folic 
acid in the second month of gestation, 636 (24.3%) discontinued this supplementation after this month 
while 1,689 (64.5%) continued it until the end of pregnancy. 
Potential confounders of cases and controls in the total dataset and in mothers with 
preconceptional (first month of gestation) folic acid supplementation are shown in Table 4. Among 
maternal variables, the proportion of professional and managerial women was higher in the 
preconceptionally folic acid supplemented women particularly in the control group. There was no 
obvious difference in the prevalence of maternal diseases and drug uses between the two study groups.  
Table 5 shows the effect of the high dose of folic acid supplementation in the first and the second 
month of gestation. The magnitude of prevention was estimated by the adjusted OR with 95% CI, all 
confounders were considered. All pregnant women who used folic acid during the second month 
irrespective of when they started in the second or in the first month of gestation but continued in the 
second month were included in this group. Three CA groups are differentiated at the evaluation of data. 
The first group of CAs includes NTDs. There was a significant reduction in the total (birth+fetal) 
prevalence of these cases after the folic acid supplementation in the first month of gestation. Some but 
not significant decrease was seen after the use of folic acid supplementation in the second month. It is 
understandable because the critical period of NTDs covers the fifth and sixth weeks of gestation (i.e. the 
first part of the second month) and the protective effect of folic acid needs some time to achieve the 
necessary blood level. 
Of 8 other “candidate” CAs, only two: posterior cleft palate and cardiovascular CAs had a 
reduction after the folic acid supplementation in the first month of gestation. The protective effect of 
folic acid supplementation in the second month of gestation was also found in two CA groups: 
cardiovascular CAs again and rectal/anal stenosis/atresia. In addition there was some reduction in the 
group of cleft lip ± palate (OR:0.82), posterior cleft palate (OR:0.70) and obstructive urinary CAs 
(OR:0.70) with the upper limit of 95% CI near to 1. Other candidate CAs such as limb reduction CAs, 
congenital pyloric stenosis and omphalocele did not show a reduction after the folic acid 
supplementation either in the first or in the second month of gestation. Though it is worth mentioning 
that the critical period of congenital pyloric stenosis is during the last trimester of pregnancy and the 
OR with 95% CI was 0.72, 0.52-1.00 after the folic acid supplementation during this period. 
Third, our findings showed an unexpected reduction in some other CAs. The prevalence at birth of 
hypospadias was lower after the folic acid supplementation both in the first and second month of 
gestation. (A more limited reduction was found after the folic acid supplementation in the third month 
of gestation, adjusted OR with 95% CI was 0.89, 0.81-0.99. It is interesting because the critical period 
of hypospadias is prior to 14
th gestational week.) The prevalence at birth of poly/syndactyly was also 
reduced after the folic acid supplementation in the first month. The total (birth+fetal) prevalence of 
multiple CAs also decreased after the folic acid supplementation both in the first and second month of 
gestation. It is not shown in Table 4, but there was a reduction of microcephaly after the folic acid Int. J. Med. Sci. 2004 1(1): 50-61  55 
supplementation in the third month of gestation (OR with 95% CI: 0.36, 0.18 – 0.75). It is also 
interesting because the critical period of this CA is after the third month of gestation. Finally, it is 
important to note that the group of other CAs also showed a reduction both in the first and second 
month of gestation. However, 13 CA-groups were included in the other CA group and each of them did 
not show significant reduction separately.  
Finally it is necessary to stress that there was a significant reduction after the high dose of folic 
acid supplementation in the first and second month of gestation in the total group of CAs. The level of 
this decrease was 24% and 21%, respectively.    
Table 6 demonstrates the comparison of preventive effectiveness of the folic acid (0.8 mg) 
containing multivitamin in the pooled dataset of the two Hungarian intervention trials and the high dose 
of folic acid supplementation during the first and second month of gestation in the dataset of the 
HCCSCA. These findings will be discussed in the next section of the paper. 
4.  Discussion 
The comparison of the results of the two Hungarian intervention trials and the HCCSCA provide 
an opportunity to estimate the preventive effectiveness of a folic acid (low dose: 0.8 mg) containing 
multivitamin and the high dose of folic acid alone for NTD and other CAs. 
The multivitamin (Elevit pronatal
®) studied seems to be more effective for the reduction of NTD 
than high dose of folic acid. These findings are in agreement with the results of two recurrent NTD 
studies. Smithells et al. [20] used a multivitamin containing 0.36 mg of folic acid and they were able to 
prevent 91% of recurrent NTD. The MRC Vitamin Study [1] used 4 mg of folic acid and 71% of 
recurrent NTD were prevented. Thus the additive and/or synergestic effect of B vitamins such as folic 
acid, vitamins B2 [21], B6 [22] and B12 [23] can improve the preventive effectiveness of 
multivitamins. (The different possible preventive mechanisms of multivitamins and/or folic acid for 
NTD and other CAs [14] are not discussed here.) On the other hand, 0.4 mg of folic acid was used in 
China as part of a public health campaign and the risk of NTD was reduced by 79% in areas with high 
rates of NTD (3.3 – 5.5 per 1,000) while the reduction was 49% in areas with low rates (0.8 – 1.0 per 
1,000) [24]. Thus the gene-environmental interaction in the populations studied seems to be more 
important than the dose of folic acid. 
Among candidate CAs, a reduction was found in the prevalence at birth of cardiovascular CAs 
both after the use of the multivitamin and the high dose of folic acid. However, the preventive 
effectiveness of the multivitamin was higher. A reduction in the occurrence of urinary tract CAs, 
congenital pyloric stenosis and limb reduction CAs was found only after the use of multivitamins in our 
intervention trials and other observational studies [6]. However, the multivitamin used in our 
intervention trials did not reduce the prevalence at birth of orofacial cleft, while the high dose of folic 
acid showed some preventive effect particularly for posterior cleft palate. Thus a dose dependent 
preventive effect of folic acid seems to be plausible [25]. Folic acid seems to be also effective for the 
prevention of rectal/anal stenosis/atresia. Omphalocele did not show any reduction after either 
multivitamin or folic acid supplementation in our data sets. (Unfortunately the differentiation of 
gastroschisis from omphalocele is not performed correctly in all cases of the HCCSCA). 
Three CAs: hypospadias, poly/syndactyly and multiple CAs showed also reduction after the use of 
high dose of folic acid while a similar decrease was not found in their occurrence after the multivitamin 
use in the two intervention trials and in other observational studies [6]. Further studies are needed to 
differentiate the chance and vitamin-dependent causal effect in these CAs. It is important to stress that 
the group of other CAs including 13 CA-groups also showed a reduction, thus we can hope that some 
other CAs may have only a preventable fraction by folic acid. 
For all CAs the risk reduction associated with periconceptional multivitamin supplementation was 
47% in the Hungarian RCT [2-5] while it was only 26% in the Hungarian TCT [7] though the same 
multivitamin was used. However, the predominance of participants were primiparous at low risk in the 
Hungarian RCT while the major part of participants had a high risk in the Hungarian TCT (see Table 1). 
About 20% risk reduction was found in the Atlanta case-control study after periconceptional 
multivitamin use [6]. The results of our recent Hungarian case-control study showed a 24% reduction 
for all CAs after the periconceptional use of high dose of folic acid. 
Of course, the valid results of studies are determined by the quality of study design and experts. 
The RCT had only one problem and it was the limited statistical power due to the number of subjects. Int. J. Med. Sci. 2004 1(1): 50-61  56 
The TCT was complicated by the unexpected high participation of pregnant women at high risk. Here 
the strengths and weaknesses of the HCCSCA are summarized.  
The strengths of the HCCSCA are as follows: 
1. Large and population-based data set, including 30,054 pregnant women who received folic acid 
supplementation in a racially homogeneous European-Caucasian population. 
2. Matching of cases with controls. 
3. Good compliance by the mothers in responding to the questionnaire. 
4.Availability of prospective and medically recorded data in folic acid supplementation in a certain 
portion of the study groups. 
5. Knowledge of exposure time, i.e. folic acid supplementation. 
6. Knowledge of confounders. 
7. A high validity in the diagnosis of CAs. 
However, this data set also has some limitations: 
1. The response rate was 84% for cases, and 83% for controls; however, there was an active 
follow-up for all mothers in the case group who did not respond to the questionnaire, but only 200 
population control mothers with no response were visited at home. However, the prevalence of folic 
acid supplementation did not differ significantly between the respondents and the nonrespondent 
controls [19].
 
2. Most folic acid uses were based on information that was collected retrospectively from mothers. 
One explanation might be that folic acid was prescribed by other physicians independently of antenatal 
care. In addition a smaller proportion of cases than controls had medically recorded exposure [26], but 
the information of mothers is valid. 
3. The absolute number of women taking folic acid in the first month of gestation was small, which 
limited the statistical power. 
4. Most women with folic acid supplementation were treated with other drugs and a small portion 
with multivitamins as well. However, their proportion was similar in the two study groups and other 
medicine uses were considered as a confounder.  
5. There is an underascertainment of medicine use during pregnancy [19].  
The major methodological problem is the comparability of results derived from intervention trials 
and CA-surveillance because the data of the latter depends on the responsibility and expertise of 
hundred of medical doctors. This dilemma explains that our comparative findings can only be 
considered as crude estimates. Nevertheless, our study is the first in the international literature which 
compare the preventive effectiveness of the multivitamin studied and high dose of folic acid in the same 
population.  
In conclusion, findings are consistent that periconceptional multivitamin and folic acid 
supplementation reduce the overall occurrence of CAs, in addition to the demonstrated effect on NTD. 
At present we can identify some other specific CAs which seem to be appropriate for the primary 
prevention by multivitamins or folic acid, though further studies are needed to determine the optimal 
method and the possible risk reduction. However, any risk reduction of specific and overall CAs is 
important from public health aspect. At present we can recommend the daily use of multivitamin 
supplement including 0.4 – 0.8 mg of folic acid with a healthy diet and lifestyle for women who want to 
do their best to have a baby without NTD and some other CAs.  
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Tables 
Table 1. Study design and characteristics of the two Hungarian intervention trials 
Study design  Randomised controlled trial  Two-cohort controlled trial 
Study medicine  Elevit prenatal 
(containing 0.8 mg of folic acid, 
vitamins B2, B6 and B12) 
Elevit prenatal 
(containing 0.8 mg of folic acid, 
vitamins B2, B6 and B12) 
Duration of treatment  Periconceptional 
(one month before, three months 
after conception) 
Periconceptional 
(one month before, three months 
after conception) 
Recruitment of supplemented 
participants 
Periconceptional care 
(coordinating center in 
Budapest) 
Periconceptional care 
(all centers in Hungary) 
Number of supplemented 
participants 
2,819 (confirmed pregnancy)  3,069 (at 14
th week of gestation) 
Recruitment of unsupplemented 
participants 
Periconceptional care 
(coordinating center in 
Budapest) 
Regional antenatal care 
(all clinics in Hungary) 
Number of unsupplemented 
participants 
2,683 (confirmed pregnancy)  3,069 (at 14
th week of gestation) 
Selection or matching criteria of 
supplemented and 
unsupplemented women 
Randomization  Age, socioeconomic status, 
region 
Characteristics of participants  Predominance of primiparous  Predominance of pregnant 
women at high risk 
Primary endpoints  
     (No.) 
Informative offspring 
(2,471 vs 2,391) 
Informative offspring 
(3,056 vs 3,056) 
Study period  February 1, 1984 – April 30, 
1991 
May 1, 1993 – April 30, 1996 
Evaluation of pregnancy 
outcomes 
April 30, 1992  April 30, 1997 
End of follow-up  April 30, 1993  April 30, 1993 
Table 2 Total (birth + fetal) prevalence of neural-tube defects (NTDs) in informative offspring of 
women taking folic acid-containing multivitamin supplement and no (multivitamin or folic acid) 
supplement during periconceptional period in the two Hungarian intervention trials. 
Intervention trials  Supplement  No supplement 
Randomized controlled trial (RCT)    
   Number of offspring  2,471  2,391 
   Expected/observed number of NTD  6.9/0  6.7/6* 
   RR (with 95% CI)  0.07 (0.04-0.13) 
Two-cohort controlled trial (TCT)    
   Number of offspring  3,056  3,056 
   Expected/observed number of NTDs  8.5/1**  8.5/9*** 
   OR (with 95% CI)  0.11 (0.01-0.91) 
Pooled data    
   Number of offspring  5,527  5,447 
   Expected/observed number of NTDs  15.4/1  15.2/15 
   OR (with 95% CI)  0.08 (0.01-0.47) 
* Anencephaly 2, Anencephaly +spina bifida (lumbal, thoracolumbal) 2, Spina bifida 2, thoracolumbal 1, 
lumbosacral 1 
** Anencephaly 1 
***Anencephaly 1, Spina bifida 8, thoracolumbal 1, lumbal 4, lumbal 4, lumbosacral 3 Int. J. Med. Sci. 2004 1(1): 50-61  59 
Table 3. The efficacy of periconceptional folic acid-containing multivitamin supplementation in the 
primary prevention of some major CA-groups in the two Hungarian intervention trials 
Isolated CA groups  Hungarian intervention trials   
  RCT TCT  Pooled  data 
  No 
supplement 
(n=2,391) 
Supple-
ment 
(n=2,471) 
No 
supplement 
(n=3,056) 
Supplement 
(n=3,056) 
No 
supplement 
(n=5,447) 
Supple-
ment 
(n=5,527) 
Urinary tract CAs           
   Obstructive CAs           
      Pelvicureteric 
junction 
4 0  13 2 17  2 
      Other locations  1  1  6 8 7  9 
   Renal a/dysgenesis  3  0  0 2 3  2 
   Cystic kidney  1  1  0 2 1  3 
Total  9 2 19 14 28  16 
OR (95% CI)  0.21 (0.05, 0.95)  0.71 (0.33, 1.50)  0.56 (0.30, 1.04) 
Cardiovascular CAs           
   Conotruncal           
      Ventricular septal 
defect 
8 2  19 5 27  7 
      Others  2  1  1 3 3  4 
   Subtotal  10  3  20 8 30  11 
   Others  10 7 30 23 40  30 
Total  20  10  50 31 70  41 
OR (95% CI)  0.42 (0.19, 0.98)  0.60 (0.38, 0.96)  0.57 (0.39, 0.85) 
Limb reduction CAs           
   Terminal transverse  2  1  3 1 5  2 
   Others  3  0  0 0 3  0 
Total  5  1  3 1 8  2 
OR (95% CI)  0.19 (0.03, 1.18)  0.33 (0.01, 3.71)  0.25 (0.05, 1.16) 
Congenital pyloric 
stenosis 
8 2 2  0 10  2 
OR (95% CI)  0.24 (0.05, 1.14)  0.00 (0.00, 26.8)  0.20 (0.04, 0.90) 
Orofacial clefts           
   Cleft lip+palate  3  4  2 3 5  7 
   Posterior  cleft 
palate 
2  0  1 1 3  1 
Total  5  4  3 4 8  8 
OR (95% CI)  0.77 (0.22, 2.69)  1.63 (0.31, 2.88)  0.99 (0.37, 2.63) 
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Table 4. Basic characteristics of cases and controls in the total datasets and in mothers who used folic 
acid in the first month of pregnancy, i.e. preconceptionally 
  Cases Controls 
  Total 
dataset 
(N=22,843) 
Folic acid use 
in the 
first month 
(N=684) 
Total 
dataset 
(N=38,151) 
Folic acid use 
in the 
first month 
(N=1,526) 
  N %  N  % N  % N % 
Maternal age (yr)               
     < 25  10,945  47.9  327  47.8  17,994  47.2  746  48.9 
     25 – 29   7,154  31.3  236  34.5  12,885  33.8  513  33.6 
     > 29  4,744  20.8  121  17.7  7,272  19.1  267  17.5 
Mean (± S.D.)  25.4 (5.3)  25.2 (4.9)  25.4 (4.9)  25.3 (4.8) 
Birth order               
     1  1,299  62.3  429  62.7  24,184  63.4  949  62.2 
     >  2  8,614  37.7  255  37.3  13,967  36.6 577 37.8 
Mean (± S.D.)  1.9 (1.1)  1.8 (1.1)  1.7 (0.9)  1.7 (0.9) 
Unmarried  1,040  4.5  28  4.1  1,217  3.2 34 2.2 
Employment status               
     Professional  1,091  8.3  74  10.8  4,353  11.4  202  13.2 
     Managerial  4,968  21.7  191  27.9  10,134  26.6  479  31.4 
     Skilled worker  6,329  27.7  199  29.1  11,690  30.6  429  28.1 
     Semiskilled worker  3,869  16.9  106  15.5  5,783  15.2  203  13.3 
     Unskilled worker  1,503  6.6  34  5.0  1,859  4.9  61  4.0 
     Housewife  2,128  9.3  36  5.3  2,038  5.3  58  3.8 
     Others  2,145  9.4  44  6.4  2,294  6.0  94  6.2 
Pregnancy supplements               
     Multivitamins  in  the 
first gestational month 
1,330  5.8 45 3.4  2,509 6.9 110 4.4 
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Table 5. The dataset of the HCCSCA, 1980-1996 regarding high dose of folic acid supplementation in 
the first and second month of gestation. 
  Grand 
total 
First month  POR        95% CI  Second 
month 
POR         95% 
CI 
  No.  No. %    No. %   
Total controls  38,151 1,526 4.0  referent  2,617 6.9  referent 
Neural-tube defects  1,202 32  2.7  0.68  0.47 – 0.97  66 5.5  0.80  0.62 – 1.03 
Candidate CAs                 
     Cleft lip ± palate  1,374  48  3.5  0.89  0.67 – 1.20  76  5.5  0.82  0.64 – 1.03 
     Posterior  cleft 
palate 
601 12  2.0  0.50  0.28 – 0.89  29 4.8  0.70  0.48 – 1.02 
     Cardiovascular CAs  4,479 142  3.2  0.81  0.68 – 0.96  227 5.1  0.75  0.65 – 0.86 
     Rectal/anal 
atresia/stenosis 
220 4  1.8  0.46  0.17 – 1.23  6  2.7  0.39  0.17 – 0.88 
     Obstructive  urinary 
CAs 
502 13  2.6  0.64  0.37 – 1.12  24  4.8  0.70  0.46 – 1.06 
     Limb reduction CAs  548 15  2.7  0.69  0.41 – 1.16  33  6.0  0.89  0.62 – 1.26 
     Congenital  pyloric 
stenosis 
241 11  4.6  1.16  0.63 – 2.13  11  4.6  0.65  0.35 – 1.19 
     Omphalocele  238  10  4.2  1.07  0.57 – 2.02  10  4.2  0.60  0.32 – 1.13 
New candidate CAs                 
     Hypospadias  3,038  83  2.7  0.68  0.55 – 0.86  163 5.4  0.78  0.66 – 0.92 
     Poly/syndactyly  1,744  43  2.5  0.62  0.45 – 0.84  104 6.0  0.88  0.72 – 1.08 
     Multiple CAs  1,349  34  2.5  0.64  0.45 – 0.90  69 5.1  0.75  0.59 – 0.96 
Others  7,307 237  3.2  0.80  0.70 – 0.92  403 5.5  0.79  0.71 – 0.88 
Total  22,843 684 3.0  0.76  0.70 – 0.84  1,221 5.3 0.79  0.73 – 0.84 
Table 6. Comparison of preventive effectiveness of the folic acid (0.8 mg) containing multivitamin 
(Elevit prenatal
®) in the pooled dataset of the two Hungarian intervention trials and the high dose (in 
general 6 mg) of folic acid supplementation during the first and second month of gestation in the dataset 
of the HCCSCA. 
CA groups  Intervention trials 
(multivitamin) 
HCCSCA (folic acid)               
     First month  Second month 
  OR  95% CI  OR  95% CI  OR  95% CI 
Neural-tube defects  0.08  0.01 – 0.47  0.68  0.47 – 0.97  0.80  0.62 – 1.03 
Candidate CAs          
     Cleft lip ± palate  1.42  0.42 – 4.43  0.89  0.67 – 1.20  0.82  0.64 – 1.03 
     Posterior cleft palate  0.34  0.00 – 3.23  0.50  0.28 – 0.89  0.70  0.48 – 1.02 
     Cardiovascular CAs*  0.57  0.39 – 0.85  0.81  0.68 – 0.96  0.75  0.65 – 0.86 
     Congenital  pyloric 
stenosis* 
0.20  0.04 – 0.90  1.16  0.63 – 2.13  0.65  0.35 – 1.19 
     Rectal/anal 
atresia/stenosis 
0.20  0.02 – 1.69  0.46  0.17 – 1.23  0.39  0.17 – 0.88 
     Obstructive  urinary 
CAs 
0.19  0.04 – 0.86  0.64  0.37 – 1.12  0.70  0.46 – 1.06 
     Limb reduction CAs  0.25  0.05 – 1.16  0.69  0.41 – 1.16  0.89  0.62 – 1.26 
     Omphalocele  2.01  0.44 – 10.81  1.07  0.57 – 2.02  0.60  0.32 – 1.13 
New candidate CAs          
     Hypospadias  0.62  0.32 – 1.53  0.68  0.55 – 0.86  0.78  0.66 – 0.92 
     Poly/syndactyly  0.73  0.24 – 2.31  0.62  0.45 – 0.84  0.88  0.72 – 1.08 
     Multiple CAs  0.89  0.47 – 1.68  0.64  0.45 – 0.90  0.75  0.59 – 0.96 
 